JP Morgan Chase
NVCT icon

JP Morgan Chase’s Nuvectis Pharma NVCT Stock Holding History

JP Morgan Chase’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$48.5K Buy
6,472
+90
+1% +$771 ﹤0.01% 6214
2025
Q4 		$48.2K Buy
6,382
+1,065
+20% +$6.94K ﹤0.01% 6244
2025
Q3 		$32K Sell
5,317
-946
-15% -$6.5K ﹤0.01% 6369
2025
Q2 		$46.8K Buy
6,263
+6,084
+3,399% +$55.2K ﹤0.01% 5951
2025
Q1 		$1.75K Hold
179
– – ﹤0.01% 6565
2024
Q4 		$968 Sell
179
-13
-7% -$81 ﹤0.01% 6740
2024
Q3 		$1.21K Sell
192
-14,561
-99% -$95.8K ﹤0.01% 6698
2024
Q2 		$93.4K Buy
14,753
+9,588
+186% +$65.2K ﹤0.01% 5545
2024
Q1 		$42.4K Buy
5,165
+263
+5% +$2.24K ﹤0.01% 6002
2023
Q4 		$40.9K Hold
4,902
– – ﹤0.01% 6057
2023
Q3 		$63.2K Sell
4,902
-558
-10% -$8.08K ﹤0.01% 5719
2023
Q2 		$87.2K Buy
+5,460
New +$87.2K ﹤0.01% 5523

Other funds holding NVCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

JP Morgan Chase's NVCT Position: Q1 2026 in Review

JP Morgan Chase increased its Nuvectis Pharma (NVCT) stake by 1.4% in Q1 2026, buying an estimated $771 and bringing the position to 6,472 shares worth $48.5K. The position accounts for ﹤0.01% of the portfolio, ranked #6214.

JP Morgan Chase first reported a position in NVCT in Q2 2023 and has held it in 12 quarters since. The position peaked at $93.4K in Q2 2024. 62 funds tracked by Wall St. Rank hold NVCT as of Q1 2026.

  • JP Morgan Chase held 6,472 shares of Nuvectis Pharma worth $48.5K as of Q1 2026.
  • JP Morgan Chase bought 90 Nuvectis Pharma shares in Q1 2026, an estimated $771.
  • Nuvectis Pharma made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6214 holding.
  • JP Morgan Chase first reported a position in Nuvectis Pharma in Q2 2023 and has held it in 12 quarters since.
  • JP Morgan Chase's Nuvectis Pharma position peaked at $93.4K in Q2 2024.
  • 62 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.